
Please try another search
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension; iAccess, a precision blade; and iPRIME, a viscoelastic delivery system. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Name | Age | Since | Title |
---|---|---|---|
Thomas W. Samuelson | - | - | Member of Scientific Advisory Board |
Richard L. Lindstrom | 74 | - | Member of Scientific Advisory Board |
Gilbert H. Kliman | 63 | 2020 | Independent Director |
Ike K. Ahmed | - | - | Member of Scientific Advisory Board |
Kerry D. Solomon | - | - | Member of Scientific Advisory Board |
Richard A. Lewis | - | - | Member of Scientific Advisory Board |
Eric D. Donnenfeld | 66 | - | Member of Scientific Advisory Board |
Edward J. Holland | - | - | Member of Scientific Advisory Board |
Leana S. Wen | 39 | 2021 | Independent Director |
Mark J. Foley | 57 | 2014 | Lead Independent Director |
Denice M. Torres | 62 | 2021 | Independent Director |
Kuldev Singh | - | - | Member of Scientific Advisory Board |
John Berdahl | - | - | Member of Scientific Advisory Board |
Robert J. Cionni | - | - | Member of Scientific Advisory Board |
Aimee S. Weisner | 53 | 2014 | Independent Director |
Thomas William Burns | 61 | 2002 | Chairman & CEO |
Marc A. Stapley | 53 | 2014 | Independent Director |
David Frank Hoffmeister | 68 | 2014 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review